Netarsudil

(Rhopressa®)

Rhopressa®

Drug updated on 11/13/2023

Dosage FormSolution (topical; 0.02%)
Drug ClassRho Kinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Product Monograph / Prescribing Information

Document TitleYearSource
Rhopressa (netarsudil) Prescribing Information.2019Aerie Pharmaceuticals, Inc., Irvine, CA

Systematic Reviews / Meta-Analyses